Title : Randomized Controlled Trial of the Gastrin/CCK2 Receptor Antagonist Netazepide in Patients with Barrett's Esophagus.

Pub. Date : 2021 Jun

PMID : 33782049






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Netazepide treatment resulted in increased expression of genes related to gastric phenotype (TFF2, MUC5B) and certain cancer-associated markers (REG3A, PAX9, MUC1), and decreased expression of intestinal markers MUC2, FABP1, FABP2, and CDX1. YF 476 fatty acid binding protein 2 Homo sapiens